Loading...
Market
How many countries will approve Sanofi's tolebrutinib for non-relapsing secondary progressive MS by December 31, 2024?
2
Resolution / Starting Odds
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Official announcements from health regulatory agencies globally
Story
Sanofi's Tolebrutinib Delays Progressive MS Disability by 31%
Sep 20, 2024, 09:40 AM
Sanofi has announced that its experimental drug, tolebrutinib, has shown promising results in delaying the progression of disability in patients with non-relapsing secondary progressive multiple sclerosis. According to data from a phase 3 trial, tolebrutinib delayed the worsening of the disease by 31%. This development provides hope for patients who currently have no effective treatment options. Sanofi's data indicates a significant 31% delay in disability progression onset.
View original story
Similar markets
FDA only • 25%
EMA only • 25%
Both FDA and EMA • 25%
Neither • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
Significantly better • 25%
Moderately better • 25%
Similar • 25%
Worse • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
<10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
>30 countries • 25%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%